Loading...
XSHG
605199
Market cap504mUSD
Dec 05, Last price  
8.92CNY
1D
0.45%
1Q
-3.36%
IPO
8.52%
Name

Hainan Huluwa Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHG:605199 chart
P/E
P/S
2.52
EPS
Div Yield, %
1.40%
Shrs. gr., 5y
-0.12%
Rev. gr., 5y
1.60%
Revenues
1.41b
-25.81%
487,353,546655,005,486983,772,6031,305,918,0581,161,705,7691,353,793,1791,515,046,4531,905,182,1631,413,548,352
Net income
-274m
L
33,762,89922,127,905100,538,817120,329,315121,502,48272,137,85885,681,971106,497,782-274,457,302
CFO
-149m
L
64,964,80089,962,55131,796,623144,512,8103,299,892102,483,892238,711,44228,252,316-149,115,614
Dividend
Jul 16, 20240.125 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hainan Huluwa Pharmaceutical Group Co., Ltd. engages in the research and development, production, and sale of drugs in the areas of Children's respiratory and digestive systems in China. Its primary products include 4 grams of pediatric lung heat cough granules and capsules. The company was founded in 2005 and is based in Haikou, China.
IPO date
Jul 10, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT